Fosun Pharma’s subsidiary, Fosun Pharma Industrial, has entered a licence agreement to grant ex-China rights for its experimental respiratory drug, XH-S004, to Expedition Therapeutics.
This agreement grants US-based Expedition the rights to independently develop, manufacture and commercialise XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor developed by Fosun Pharma.
The rights are applicable in all regions worldwide, excluding the Chinese mainland, Hong Kong Special Administrative Region (SAR) and Macau SAR.
Fosun Pharma will retain the rights to develop, manufacture and commercialise XH-S004 in these specific regions.
Expedition will make substantial financial commitments. It will provide up to $120m, including upfront and milestone payments during development phases.
Should XH-004 achieve certain sales targets within licensed territories, Expedition could pay up to an additional $525m under contract terms.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFosun Pharma chairman Chen Yuqing stated: 鈥淏y working together with Expedition, the professional teams and rich industry experience of both parties will provide strong support for the global development and commercialisation of XH-S004, further expanding the accessibility of this product and enabling global patients to benefit from this innovative therapy as soon as possible.鈥�
XH-S004 treats inflammatory respiratory conditions due to its novel mechanism of action as an orally administered DPP-1 inhibitor.
Its ability to reduce inflammation and prevent infection cycle progression offers hope for patients suffering from non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease (COPD).
Currently undergoing clinical trials in China, XH-S004 is being studied for its efficacy against non-cystic fibrosis bronchiectasis in Phase II trials and COPD in Phase Ib trials.
With no similar small-molecule orally administered inhibitors yet approved worldwide, this drug holds potential as a pioneering treatment option upon successful development and regulatory approval.
Expedition chairman and CEO Yi Larson stated: 鈥淲e are pleased to be working with Fosun Pharma, one of the leading pharmaceutical companies in China. XH-S004 is an exciting compound that targets neutrophilic inflammation, an important underlying driver of a number of chronic respiratory diseases.
鈥淲e look forward to partnering with Fosun Pharma in the development of XH-S004 for COPD and other neutrophilic inflammatory diseases to address the significant unmet medical need.鈥�
